AbbVie Inc
USUSDAbbVie Inc (US:ABBV) — Biotechnology: Pharmaceutical Preparations. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 4. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par uzņēmumu
- Tīmekļvietne
- abbvie.com
- Nozare
- Health Care · Biotechnology: Pharmaceutical Preparations
- Galvenā mītne
- North Chicago, United States
- Izpilddirektors
- Robert A. Michael
- Darbinieki
- 57 000
- Dibināts
- 2012
- Apgrozībā esošās akcijas
- Brīvā apgrozība
- 1.76 mljrd.
- Tirgus kapitalizācija
- 470.55 mljrd. USD
- Iekšējās personas
- 0.11%
- Institucionālie investori
- 77.37%
- Nozare (SIC)
- Pharmaceutical Preparations
- Juridiskā forma
- XTIQ
- ISIN
- US00287Y1091
- LEI
- FR5LCKFTG8054YNNRU85
- Izmaksas koeficients
- 190%
- FCF
- 18.2 mljrd. USD66%
- Parāds
- 70.8 mljrd. USD3.5 g. FCF
- Dividenžu stāžs
- 13 g.
- Peļņa, FCF un izmaksātās dividendes — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Dividendes
AbbVie Inc (ABBV) izmaksā dividendes reizi ceturksnī. Pēdējo 12 mēnešu laikā tika samaksāts 6.83 USD par akciju (maksājumi: 4). Tas ir aptuveni 2.51% no pašreizējās akciju cenas. Nākamais ex-dividendes datums ir 15.10.2026: 1.73 USD par akciju, izmaksa 16.11.2026. Nepārtrauktu dividenžu gadi: 13.
| Ex-datums | Izmaksa | Summa | % | Veids | Tikeris |
|---|---|---|---|---|---|
| 2026-10-15 paziņots | 2026-11-16 | 1.7300 USD | 0.6/2.5 % | ceturkšņa | US:ABBV |
| 2026-07-15 | 2026-08-14 | 1.7300 USD | 0.6/2.5 % | ceturkšņa | US:ABBV |
| 2026-04-15 | 2026-05-15 | 1.7300 USD | 0.6/2.5 % | ceturkšņa | US:ABBV |
| 2026-01-16 | 2026-02-17 | 1.7300 USD | 0.6/2.4 % | ceturkšņa | US:ABBV |
| 2025-10-15 | 2025-11-14 | 1.6400 USD | 0.6/≈2.4 % | ceturkšņa | US:ABBV |
| 2025-07-15 | 2025-08-15 | 1.6400 USD | 0.6/≈2.4 % | ceturkšņa | US:ABBV |
| 2025-04-15 | 2025-05-15 | 1.6400 USD | 0.6/≈2.4 % | ceturkšņa | US:ABBV |
Ziņas šonedēļ
Preses relīzes no uzņēmuma investoru mājaslapas, kas tiek atjauninātas katru dienu. Saites ved uz uzņēmuma mājaslapu. Virsraksti ir oriģinālvalodā, kā uzņēmuma mājaslapā.
Lielākie akcionāri
| Turētājs | Daļa | Akcijas | Pārskata datums |
|---|---|---|---|
| BlackRock | 8.46% | 149.49 milj. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 115.4 milj. | 2026-06-30 |
| State Street Corporation | 4.67% | 82.6 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 56.09 milj. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.74% | 48.48 milj. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.71% | 47.86 milj. | 2026-06-30 |
| Geode Capital Management… | 2.66% | 47 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 45.78 milj. | 2026-06-30 |
| Morgan Stanley | 2.2% | 38.9 milj. | 2026-06-30 |
| Capital Research Global… | 1.7% | 30.1 milj. | 2026-06-30 |
| NORGES BANK | 1.45% | 25.55 milj. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 23.84 milj. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 22.85 milj. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 21.61 milj. | 2026-08-31 |
| Bank of America Corporat… | 1.2% | 21.24 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 16.82 milj. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 12.7 milj. | 2026-08-31 |
| AMERICAN MUTUAL FUND | 0.63% | 11.15 milj. | 2026-07-31 |
| Capital Income Builder | 0.57% | 10.06 milj. | 2026-07-31 |
| VANGUARD SPECIALIZED FUN… | 0.57% | 10 milj. | 2026-07-31 |
| GONZALEZ RICHARD A (Dire… | ≈0.02% | 386 479 | 2025-03-31 |
| SALEKI-GERHARDT AZITA (C… | ≈0.01% | 220 682 | 2026-02-18 |
| MICHAEL ROBERT A. (Chief… | ≈0.01% | 215 260 | 2026-02-18 |
| FREYMAN THOMAS C (Direct… | ≈0.01% | 135 751 | 2026-05-08 |
| STEWART JEFFREY RYAN (Of… | ≈0.01% | 108 321 | 2026-02-18 |
| DONOGHOE NICHOLAS (Offic… | ≈0% | 74 430 | 2026-08-14 |
| REENTS SCOTT T. (Chief F… | ≈0% | 60 415 | 2026-02-18 |
| THAKKAR ROOPAL (Officer) | ≈0% | 60 413 | 2026-02-18 |
| TILTON GLENN FLETCHER (D… | ≈0% | 51 914 | 2025-05-09 |
| RAPP EDWARD J (Director) | ≈0% | 45 964 | 2026-05-08 |
| The Vanguard Group | — | — | — |
